Ametropia and presbyopia successfully treated with diffractive bifocal IOL

Article

Bilateral implantation of the Acri.LISA 366D diffractive bifocal IOL is effective in ametropic and presbyopic eyes, according to findings published in the European Journal of Ophthalmology

Bilateral implantation of the Acri.LISA 366D diffractive bifocal IOL is effective in ametropic and presbyopic eyes, according to findings published in the European Journal of Ophthalmology.

A team led by Dr José F. Alfonso, Instituto Oftalmológico Fernández-Vega, Oviedo, Spain, studied 66 eyes in 33 consecutive patients. They were examined after refractive lens exchange (RLE) and implanted with the IOL. Eyes were split into myopic and hyperopic groups. The patient's monocular uncorrected distance visual acuity, best-corrected distance visual acuity (BCVA), uncorrected distance near visual acuity, and best distance-corrected near visual acuity (BCNVA) were measured preoperatively and at 6 months post-op.

The results showed that in the myopic group 2 eyes lost one line, 4 eyes gained 1 line and 6 eyes gained 2 lines. The hyperopic group 11 eyes lost 1 line, 8 eyes gained 1 line and 7 eyes gained 2 lines.

It was concluded that the use of Acri.LISA 366DD after RLE is an effective procedure for the treatment of presbyopia and ametropia.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.